Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
SAN FRANCISCO, June 05, 2024--New data from Vir Biotechnology reinforces the potential for a transformative treatment for hepatitis delta, the most severe form of viral hepatitis.